Protalix BioTherapeutics Inc

Research Protalix BioTherapeutics Inc (PLX) on Bullrun: valuation model: 9.6% overvalued, market cap USD 189.34M, P/E 12.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPLX
• ExchangeNYSE MKT
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal9.6% overvalued
• Market capUSD 189.34M
• P/E12.8
• Financial periodFY2025
• RevenueUSD 52.74M
• Revenue growth-1.2%
• Net income-USD 6.60M
• Free cash flow-USD 13.63M
• Gross margin48.8%

Valuation Snapshot

Bullrun's latest valuation model marks Protalix BioTherapeutics Inc as 9.6% overvalued; latest market cap is USD 189.34M; P/E is 12.8.

About Protalix BioTherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Frequently asked questions

Is Protalix BioTherapeutics Inc overvalued or undervalued?

Bullrun's valuation model currently marks Protalix BioTherapeutics Inc as 9.6% overvalued.

What is Protalix BioTherapeutics Inc's market cap?

Protalix BioTherapeutics Inc's market capitalization is USD 189.34M.

What is Protalix BioTherapeutics Inc's P/E ratio?

Protalix BioTherapeutics Inc's price-to-earnings (P/E) ratio is 12.8.

What does Protalix BioTherapeutics Inc do?

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease;